The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations

被引：0
|
作者：
Kobayashi, Takashi [1 ]
Koizumi, Tomonobu [1 ]
Tanabe, Tsuyoshi [1 ]
Tsushima, Kenji [1 ]
Urushihata, Kazuhisa [1 ]
Yamamoto, Hiroshi [1 ]
Hanaoka, Masayuki [1 ]
Kubo, Keishi [1 ]
Koyama, Shigeru [2 ]
Ooura, Nariaki [3 ]
机构：
[1] Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano 390, Japan
[2] Nagano Red Cross Hosp, Nagano, Japan
[3] Saku Cent Hosp, Saku, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S690 / S690
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Felip, E.
    Minotti, V.
    Tan, D.
    Wolf, J.
    Mark, M.
    Boyer, M.
    Hughes, B.
    Bearz, A.
    Moro-Sibilot, D.
    Le, X.
    Vazquez, J.
    Massuti, B.
    Liu, N.
    Hao, L.
    Cheng, Y.
    Tiedt, R.
    Cobo, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S586
  • [22] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
    Xiong, Liwen
    Lou, Yuqing
    Bai, Hao
    Li, Rong
    Xia, Jinjing
    Fang, Wentao
    Zhang, Jie
    Han-Zhang, Han
    Lizaso, Analyn
    Li, Bing
    Gu, Aiqin
    Han, Baohui
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [23] Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
    Kaburagi, Takayuki
    Satoh, Hiroaki
    Hayashihara, Kenji
    Endo, Takeshi
    Hizawa, Nobuyuki
    Kurishima, Koichi
    Nishimura, Yoshihiro
    Hashimoto, Toshio
    Nakamura, Hiroyuki
    Kishi, Koji
    Inagaki, Masaharu
    Nawa, Takeshi
    Ichimura, Hideo
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Fukuoka, Toshihiko
    Shinohara, Yoko
    Kamiyama, Koichi
    Sato, Yukio
    Sakai, Mitsuaki
    Matsumura, Takeshi
    Uchiumi, Keiko
    Furukawa, Kinya
    [J]. ONCOLOGY LETTERS, 2013, 5 (02) : 435 - 439
  • [24] Retrospective Analysis of Clinical Efficacy of Erlotinib in Patients with Non-Small Cell Lung Cancer
    Ayyildiz, Aylin
    Kanat, Ozkan
    Ozkaya, Guven
    Deligonul, Adem
    Gursoy, Vildan
    [J]. JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2015, 6 (02) : 212 - 215
  • [25] Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations
    Molina, M. A.
    Simonetti, S.
    Quiroga, V.
    Viteri, S.
    Campelo, R. G.
    Sanchez, J.
    Benlloch, S.
    Aldeguer, E.
    Taron, M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] ERLOTINIB IS HIGHLY ACTIVE IN SELECTED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING WILD TYPE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
    Marquez-Medina, Diego
    Gasol Cudos, Ariadna
    Taberner Bonastre, Ma Teresa
    Martin Marco, Antonio
    Gomez Falguera, Silvia
    Ortega Izquierdo, Eugenia
    Mangues Bofarul, Irene
    Salud Salvia, Antonieta
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S118 - S119
  • [27] THE FREQUENCY OF EGFR AND KRAS MUTATIONS IN THE TURKISH POPULATION WITH NON-SMALL CELL LUNG CANCER AND THEIR RESPONSE TO ERLOTINIB THERAPY
    Demiray, A.
    Yaren, A.
    Karagenc, N.
    Bir, F.
    Demiray, A. G.
    Karagur, E. R.
    Tokgun, O.
    Elmas, L.
    Akca, H.
    [J]. BALKAN JOURNAL OF MEDICAL GENETICS, 2018, 21 (02) : 21 - 26
  • [28] Clinical Significance of Erlotinib Monotherapy for Gefitinib-resistant Non-small Cell Lung Cancer with EGFR Mutations
    Koyama, Nobuyuki
    Uchida, Yoshitaka
    [J]. ANTICANCER RESEARCH, 2013, 33 (11) : 5083 - 5089
  • [29] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [30] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
12345